Female Genital Tuberculosis Diagnosis to Treatment


Article Type: Review Article
Authors: Neha Varun, Sachin Baliyan

Abstract

Genital tuberculosis in females (FGTB) is a significant cause of morbidity. Mycobacterium tuberculosis is a causative agent for tuberculosis (TB). In majority of cases tubes are involved in almost 90-100% of cases. Endometrium is the next commonly involved organ (50-80%), ovarian involvement is seen in 20-30% of cases followed by cervical involvement (5-15%). Vulva and vagina are rarely involved (1-2%). Diagnosis of FGTB is traditionally made by the presence of tubercular bacilli on microscopic examination or culture of endometrial biopsy specimen or granuloma in histopathological examination. Polymerase chain reaction have false positive results and as an isolated test it is not enough to detect the condition. Gold standard investigation for the diagnosis of FGTB is hysteroscopy and laparoscopy. Genital tuberculosis falls under category 1 of Directly Observed Treatment Short Course (DOTS) treatment and antitubercular treatment is given for 6 months. Therapy consist of initial 2 months of rifampicin, isoniazid, pyrazinamide and ethambutol and 4 months treatment with two drugs i.e. rifampicin and isoniazid. Surgical treatment has a very limited role, particularly for the drainage of residual tubercular abscess.

Keywords: 
Issue Number: Issue -2   September December 2018
Pages - 51-102
DOI:
Full text PDF

© 2018 | PAJOG All rights reserved.

TOP